But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance ...

(Reuters) - President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Eye disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new ...

On Wednesday, Stocks rose for a second consecutive day as investors moved past concerns over trade disputes that had ...

Researchers observed improvements in rates of burnout and work-life integration challenges among a cohort of U.S. medical oncology fellows in 2023 vs. 2013, but challenges remain, according to survey ...